Skip to main content
. 2022 Feb 25;54(2):194–205. doi: 10.1038/s12276-022-00735-x

Fig. 2. Knockdown of IGF2BP3 significantly inhibits AML progression in vitro.

Fig. 2

a The protein expression level of IGF2BP3 in various hematologic tumor cell lines was measured by western blotting. b The knockdown efficiency of IGF2BP3 shRNAs (shIGF2BP3#1 and shIGF2BP3#2) delivered via lentiviral vectors in HL-60 and KG-1 cell lines was confirmed by western blotting. GAPDH was used as the internal reference. c Cell proliferation was measured by a CCK-8 assay at different time points (0, 24, 48, 72, and 96 h) in HL-60 and KG-1 cells after shRNA transduction. d The transduction efficiency after puromycin selection was evaluated by GFP fluorescence imaging in both cell lines. e Flow cytometry (representative images are presented) was used to confirm the induction of apoptosis by IGF2BP3 knockdown. f Western blotting was used to explore apoptosis-related protein levels. The levels of cleaved caspase-3 and Bax were increased but the level of Bcl-2 was decreased under shIGF2BP3 treatment compared with control treatment. g Flow cytometry (representative images are presented) was used to analyze the cell cycle distribution. *P < 0.05; **P < 0.01; ***P < 0.001.